249 related articles for article (PubMed ID: 11174624)
1. Risk of Guillain-Barré syndrome after measles-mumps-rubella vaccination.
Patja A; Paunio M; Kinnunen E; Junttila O; Hovi T; Peltola H
J Pediatr; 2001 Feb; 138(2):250-4. PubMed ID: 11174624
[TBL] [Abstract][Full Text] [Related]
2. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study.
Mrozek-Budzyn D; Kiełtyka A; Majewska R
Pediatr Infect Dis J; 2010 May; 29(5):397-400. PubMed ID: 19952979
[TBL] [Abstract][Full Text] [Related]
3. Relationship between occurrence of Guillain-Barre syndrome and mass campaign of measles and rubella immunization in Iranian 5-14 years old children.
Esteghamati A; Gouya MM; Keshtkar AA; Mahoney F
Vaccine; 2008 Sep; 26(39):5058-61. PubMed ID: 18662736
[TBL] [Abstract][Full Text] [Related]
4. Two cases of Guillain-Barré syndrome during measles elimination campaign in Izmir.
Koturoglu G; Kurugol Z; Tekgul H; Ozcan T; Dizdarer C
Minerva Pediatr; 2008 Dec; 60(6):1455-7. PubMed ID: 18971907
[TBL] [Abstract][Full Text] [Related]
5. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom.
Miller E; Andrews N; Stowe J; Grant A; Waight P; Taylor B
Am J Epidemiol; 2007 Mar; 165(6):704-9. PubMed ID: 17204517
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
7. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study.
Ray P; Hayward J; Michelson D; Lewis E; Schwalbe J; Black S; Shinefield H; Marcy M; Huff K; Ward J; Mullooly J; Chen R; Davis R;
Pediatr Infect Dis J; 2006 Sep; 25(9):768-73. PubMed ID: 16940831
[TBL] [Abstract][Full Text] [Related]
8. A population-based study of measles, mumps, and rubella vaccination and autism.
Madsen KM; Hviid A; Vestergaard M; Schendel D; Wohlfahrt J; Thorsen P; Olsen J; Melbye M
N Engl J Med; 2002 Nov; 347(19):1477-82. PubMed ID: 12421889
[TBL] [Abstract][Full Text] [Related]
9. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children.
Bernsen RM; van der Wouden JC
Pediatr Allergy Immunol; 2008 Sep; 19(6):544-51. PubMed ID: 18266826
[TBL] [Abstract][Full Text] [Related]
10. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
Souayah N; Nasar A; Suri MF; Qureshi AI
J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
[TBL] [Abstract][Full Text] [Related]
11. Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Jun; 59(21):657-61. PubMed ID: 20520590
[TBL] [Abstract][Full Text] [Related]
12. [MMR vaccination and autism--a population-based follow-up study].
Madsen KM; Hviid A; Vestergaard M; Schendel D; Wohlfahrt J; Thorsen P; Olsen J; Melbye M
Ugeskr Laeger; 2002 Dec; 164(49):5741-4. PubMed ID: 12523209
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P; Lim FS; Han HH; Willems P
Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
[TBL] [Abstract][Full Text] [Related]
14. No evidence of an association between MMR vaccine and gait disturbance.
Miller E; Andrews N; Grant A; Stowe J; Taylor B
Arch Dis Child; 2005 Mar; 90(3):292-6. PubMed ID: 15723921
[TBL] [Abstract][Full Text] [Related]
15. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
17. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy.
Marin M; Nguyen HQ; Langidrik JR; Edwards R; Briand K; Papania MJ; Seward JF; LeBaron CW
Clin Infect Dis; 2006 Feb; 42(3):315-9. PubMed ID: 16392073
[TBL] [Abstract][Full Text] [Related]
18. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study.
Juurlink DN; Stukel TA; Kwong J; Kopp A; McGeer A; Upshur RE; Manuel DG; Moineddin R; Wilson K
Arch Intern Med; 2006 Nov; 166(20):2217-21. PubMed ID: 17101939
[TBL] [Abstract][Full Text] [Related]
19. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
Alfredsson R; Svensson E; Trollfors B; Borres MP
Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
[TBL] [Abstract][Full Text] [Related]
20. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.
Jacobsen SJ; Ackerson BK; Sy LS; Tran TN; Jones TL; Yao JF; Xie F; Cheetham TC; Saddier P
Vaccine; 2009 Jul; 27(34):4656-61. PubMed ID: 19520201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
